HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

PENTA

structure given in first source

Also Known As:

Org 31540; Org-31540; SR 90107; SR 90107A; natural heparin pentasaccharide; alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopy

Networked: 266 relevant articles (17 outcomes, 41 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 4088
- Polysaccharides: 2929
  - Oligosaccharides: 1372
    - PENTA: 266

Experts

1.	Kim, Sung-Hoon: 9 articles (08/2012 - 08/2005)
2.	Rofstad, Einar K: 8 articles (02/2014 - 09/2011)
3.	Ellingsen, Christine: 6 articles (02/2014 - 01/2012)
4.	Gibb, Diana M: 6 articles (01/2013 - 08/2002)
5.	Wang, Chau-Jong: 6 articles (09/2009 - 04/2004)
6.	Hompland, Tord: 5 articles (02/2014 - 01/2012)
7.	Walker, A Sarah: 5 articles (01/2013 - 08/2002)
8.	Giaquinto, Carlo: 5 articles (01/2013 - 12/2005)
9.	Lü, Junxuan: 5 articles (06/2011 - 05/2009)
10.	Zhang, Jinhui: 5 articles (02/2011 - 05/2009)

Related Diseases

1.	Sarcoidosis (Schaumann Disease) 10/01/2000 - "One year follow-up of lung clearance of 99mTc-diethylene triamine penta-acetic acid and disease activity in sarcoidosis." 11/01/1994 - "Different kinetics of lung clearance of technetium-99m labelled diethylene triamine penta-acetic acid in patients with sarcoidosis and smokers." 05/01/2002 - "Investigation of lung clearance of 99mTc-labelled diethylene triamine penta-acetic acid (DTPA) in smoking sarcoid patients has been impeded by difficulties to differ between pathology of clearance kinetics caused by sarcoidosis and by smoking. " 07/01/1999 - "The pulmonary epithelial permeability of 99mTc-DTPA (diethylene triamine penta acetate) was assessed in patients with interstitial lung diseases including radiation pneumonitis, idiopathic interstitial pneumonia/pulmonary fibrosis, sarcoidosis, unclassified interstitial pneumonia, and in healthy subjects. " 12/01/2002 - "Twelve patients with histologically proven sarcoidosis and highly suspected cardiac involvement underwent initial and 12-month follow-up cardiac assessment including cardiac MRI (T2-weighted, functional gradient echo, and T1-weighted gadolinium-diethylenetriamine penta-acetic acid-enhanced sequences). "
2.	Whooping Cough (Pertussis) 01/01/2014 - "Penta-valent-vaccine is a combination vaccine administered in a 3-dose schedule, offers protection against diphtheria, tetanus, pertussis (DPT), hepatitis B, and Haemophilus influenza type B (Hib). " 02/11/2011 - "The pagL gene from Bordetella bronchiseptica, which encodes a lipid A 3-deacylase, was expressed in Bordetella pertussis strain Tohama I. The resulting OMVs, designated OMVs(BpPagL), contain tetra- instead of penta-acylated LOS, in addition to pertussis surface immunogens such as pertactin and pertussis toxin, as the wild type OMVs. " 05/01/2000 - "To assess vaccine effectiveness through enhanced disease surveillance following the change in childhood immunization programs in 1995, when all provinces and territories chose to use polyribosyl ribitol phosphate-tetanus protein (PRP-T) Haemophilus influenzae type b (Hib) conjugate vaccine, generally in combination with diphtheria-pertussis-tetanus inactivated polio vaccine (DPT-IPV) (as PENTA vaccine) because the protective efficacy of this regimen had not been directly measured. " 09/01/2007 - "We describe the immunogenicity and reactogenicity of a combined DTPa-HBV-IPV vaccine (diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus (DTPa-HBV-IPV: Infanrix penta) ) when administered for the primary vaccination of infants resulting from a study where the primary objective was to demonstrate non-inferiority of the immune response induced by DTPa-HBV-IPV using an industrial-scale IPV production process. "
3.	Tetanus 01/01/2014 - "Penta-valent-vaccine is a combination vaccine administered in a 3-dose schedule, offers protection against diphtheria, tetanus, pertussis (DPT), hepatitis B, and Haemophilus influenza type B (Hib). " 05/01/2000 - "To assess vaccine effectiveness through enhanced disease surveillance following the change in childhood immunization programs in 1995, when all provinces and territories chose to use polyribosyl ribitol phosphate-tetanus protein (PRP-T) Haemophilus influenzae type b (Hib) conjugate vaccine, generally in combination with diphtheria-pertussis-tetanus inactivated polio vaccine (DPT-IPV) (as PENTA vaccine) because the protective efficacy of this regimen had not been directly measured. " 09/01/2007 - "We describe the immunogenicity and reactogenicity of a combined DTPa-HBV-IPV vaccine (diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus (DTPa-HBV-IPV: Infanrix penta) ) when administered for the primary vaccination of infants resulting from a study where the primary objective was to demonstrate non-inferiority of the immune response induced by DTPa-HBV-IPV using an industrial-scale IPV production process. "
4.	Diphtheria 01/01/2014 - "Penta-valent-vaccine is a combination vaccine administered in a 3-dose schedule, offers protection against diphtheria, tetanus, pertussis (DPT), hepatitis B, and Haemophilus influenza type B (Hib). " 05/01/2000 - "To assess vaccine effectiveness through enhanced disease surveillance following the change in childhood immunization programs in 1995, when all provinces and territories chose to use polyribosyl ribitol phosphate-tetanus protein (PRP-T) Haemophilus influenzae type b (Hib) conjugate vaccine, generally in combination with diphtheria-pertussis-tetanus inactivated polio vaccine (DPT-IPV) (as PENTA vaccine) because the protective efficacy of this regimen had not been directly measured. " 09/01/2007 - "We describe the immunogenicity and reactogenicity of a combined DTPa-HBV-IPV vaccine (diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus (DTPa-HBV-IPV: Infanrix penta) ) when administered for the primary vaccination of infants resulting from a study where the primary objective was to demonstrate non-inferiority of the immune response induced by DTPa-HBV-IPV using an industrial-scale IPV production process. "
5.	Idiopathic Pulmonary Fibrosis 07/01/1989 - "We measured the clearance of technetium 99m-labelled diethylene triamine penta-acetate (99m Tc-DTPA) with time from the lungs to the blood, in 11 normal, non-smoking subjects (mean age 30 years), ten non-smoking patients with cryptogenic fibrosing alveolitis (CFA, mean age 57 years) and ten patients who were non-smokers with obliterative bronchiolitis (mean age 51 years). " 12/01/2001 - "Clearance of inhaled technetium 99m-labelled diethylenetriamine penta-acetic acid ((99m)Tc-DTPA) from the lungs is a potential indicator of disease progression in patients with idiopathic pulmonary fibrosis (IPF). "

Related Drugs and Biologics

1.	Acetic Acid (Vinegar)
2.	Technetium (Technetium 99m)
3.	Pentetic Acid (DTPA)
4.	diethylenetriamine
5.	Creatinine
6.	Glucose (Dextrose)
7.	Thiamine (Aneurin)
8.	Heparin (Liquaemin)
9.	Fibrin
10.	Oleic Acid (Oleate)

Related Therapies and Procedures

1.	Stents
2.	Ligation
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Transplantation (Transplant Recipients)
5.	Nephrectomy